MicroRNA-22 impairs anti-tumor ability of dendritic cells by targeting p38.

Dendritic cells (DCs) play a critical role in triggering anti-tumor immune responses. Their intracellular p38 signaling is of great importance in controlling DC activity. In this study, we identified microRNA-22 (miR-22) as a microRNA inhibiting p38 protein expression by directly binding to the 3' untranslated region (3'UTR) of its mRNA. The p38 down-regulation further interfered with the synthesis of DC-derived IL-6 and the differentiation of DC-driven Th17 cells. Moreover, overexpression of miR-22 in DCs impaired their tumor-suppressing ability while miR-22 inhibitor could reverse this phenomenon and improve the curative effect of DC-based immunotherapy. Thus, our results highlight a suppressive role for miR-22 in the process of DC-invoked anti-tumor immunity and that blocking this microRNA provides a new strategy for generating potent DC vaccines for patients with cancer.

Citation

Xue Liang, Yu Liu, Shiyue Mei, Miaomiao Zhang, Jiaxuan Xin, Yuan Zhang, Rongcun Yang. MicroRNA-22 impairs anti-tumor ability of dendritic cells by targeting p38. PloS one. 2015;10(3):e0121510

Mesh Tags

Substances

PMID: 25826372

search → result